Royalty Pharma Plc Stock Price, News & Analysis

Royalty Pharma (Nasdaq: RPRX) acquired a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences for $310 million. Royalty Pharma purchased Blackstone’s 1% royalty on worldwide net sales covering AMVUTTRA sales beginning October 1, 2025, with the royalty extending through March 2035. AMVUTTRA is an FDA-approved RNAi therapeutic for ATTR amyloidosis; sales were approximately $1 billion in 2024 (+74% year-over-year) and analyst consensus projects sales to exceed $6 billion by 2028. The company said the deal aligns with its return targets across scenarios that include potential competition from Alnylam’s follow-on product nucresiran. Advisors on the transaction were disclosed for both parties.

Royalty Pharma (Nasdaq: RPRX) announced a fourth-quarter 2025 dividend of $0.22 per Class A ordinary share. The board approved the dividend to shareholders of record at the close of business on November 14, 2025, with payment scheduled for December 10, 2025.

This provides a cash distribution to holders of Class A ordinary shares in Q4 2025 and sets clear record and payment dates for investors.

Royalty Pharma (Nasdaq: RPRX) will report third quarter 2025 financial results on Wednesday, November 5, 2025 before U.S. markets open.

The company will host a conference call and simultaneous webcast on that day at 8:00 a.m. Eastern Time. Investors can obtain call details and view the live webcast on the company's Investors events page. A replay of the call and webcast will be archived on the website for at least 30 days.

Royalty Pharma (Nasdaq: RPRX) has appointed Dr. Ted W. Love as Lead Independent Director, as unanimously decided by the independent directors of the Board. Dr. Love, who has served as an independent director since 2020, will continue to Chair the Nominating and Corporate Governance Committee.

Dr. Love brings extensive research-based biopharma experience and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization's (BIO) Board of Directors. The appointment reinforces Royalty Pharma's commitment to strong corporate governance and strategic oversight.

Royalty Pharma (NASDAQ:RPRX) has announced its participation in Bernstein's 2nd Annual Healthcare Forum. The company will engage in a fireside chat on Tuesday, September 23, 2025 at 2:50 p.m. ET. Investors can access the webcast through Royalty Pharma's "Events" page on their investor relations website, where it will remain archived for at least thirty days.

Royalty Pharma (NASDAQ:RPRX) presented its Investor Day outlook, highlighting strong growth projections and value creation plans. The company aims to deliver Portfolio Receipts of $4.7 billion or more by 2030, exceeding consensus expectations. Since its 2020 IPO, RPRX has achieved a 12% compound annual growth rate in Portfolio Receipts and demonstrated robust financial performance with a 15% Return on Invested Capital (ROIC) and 21% Return on Invested Equity (ROIE).

The company has already deployed $9 billion of its $10-12 billion five-year capital deployment target, with $14 billion in announced transactions. The biopharma royalty market has doubled since RPRX's IPO, averaging $6.2 billion in annual transaction value. The company targets at least mid-teens average annual total shareholder return through 2030, supported by double-digit growth and dividend increases.

Royalty Pharma (NASDAQ:RPRX) announced the release of a groundbreaking Deloitte report on the biopharma royalty market. The study, titled "Role of Royalties in Funding Biopharma Innovation," gathered insights from over 110 biopharma executives, primarily CEOs and CFOs.

The report reveals that 87% of surveyed executives would consider royalties for capital raising in the next three years. Key benefits highlighted include non-dilutive nature, absence of covenants, operational control retention, single-product financing capability, and available capital scale. The study emphasizes royalties' growing importance in biopharma's diversified funding landscape, driven by positive investor perception and attractive cost of capital.

Royalty Pharma (NASDAQ:RPRX) has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company will engage in a fireside chat on Tuesday, September 9, 2025, at 3:20 p.m. ET. Investors can access the webcast through Royalty Pharma's "Events" page on their investor relations website, where it will remain archived for at least thirty days.

Royalty Pharma (Nasdaq: RPRX) has announced the pricing of $2.0 billion in senior unsecured notes across three tranches: $600 million of 4.450% Notes due 2031, $900 million of 5.200% Notes due 2035, and $500 million of 5.950% Notes due 2055.

The notes will be guaranteed by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. The offering is expected to close on September 16, 2025. The company plans to use the proceeds for general corporate purposes. Multiple financial institutions, led by BofA Securities, Goldman Sachs, J.P. Morgan, Morgan Stanley, and TD Securities, are serving as joint book-running managers.